Brenton J Baguley1, Tina L Skinner2, David G Jenkins3, Olivia R L Wright4. 1. Institute of Physical Activity and Nutrition, Deakin University, Geelong, Australia; School of Human Movement and Nutrition Sciences, The University of Queensland, Brisbane, QLD, Australia. Electronic address: b.baguley@deakin.edu.au. 2. School of Human Movement and Nutrition Sciences, The University of Queensland, Brisbane, QLD, Australia. 3. School of Human Movement and Nutrition Sciences, The University of Queensland, Brisbane, QLD, Australia; School of Health and Sport Sciences, University of the Sunshine Coast, Sippy Downs, QLD, Australia. 4. School of Human Movement and Nutrition Sciences, The University of Queensland, Brisbane, QLD, Australia; Mater Research Institute, The University of Queensland, Brisbane, QLD, Australia.
Abstract
BACKGROUND & AIMS: Cancer-related fatigue (CRF) is a prevalent and persistent symptom from androgen deprivation therapy (ADT) in prostate cancer. The Mediterranean-style dietary pattern (MED-diet) offers a plausible mechanism to mitigate CRF through reducing inflammation and improving body composition. This study aimed to evaluate the effects of a 12-week MED-diet, compared to usual care, on CRF and quality of life in men with prostate cancer treated with ADT. METHODS:Twenty-three men (65.9 ± 7.8 years; body mass index: 29.6 ± 2.7 kg/m2; ADT duration: 33.8 ± 35.6 months) receiving ADT for ≥3 months were randomly assigned (1:1) to 12-weeks of usual care or the MED-diet involving six individualised nutrition consults. Primary outcomes included CRF [Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue scale (FACIT-F) and quality of life [FACIT-General (FACIT-G)], secondary outcomes included body mass/composition and interleukin (IL)-6 and IL-8 concentrations measured at baseline, 8-weeks and 12 weeks. Intervention feasibility was measured by intervention safety, study completion rate, consult attendance, and adherence to the MED-diet through the Mediterranean-diet adherence screener (MEDAS). Intention to treat linear mixed models were used to determine changes in outcomes between the MED-diet and usual care at baseline, 8-weeks and 12-weeks. RESULTS: The MED-diet improved CRF (FACIT-F) at 8-weeks [+4.8 (0.0, 9.8); P = 0.05] and 12-weeks [+7.2 (2.2, 12.0); P = 0.005], quality of life (FACIT-G) at 12-weeks [+9.2 (2.7, 15.8); P = 0.006], reduced total body mass at 8-weeks [-2.51 kg (-4.25, -0.78); P = 0.005] and 12-weeks [-2.97 kg (-4.71, -1.25); P = 0.001], lean mass at 8-weeks [-1.50 kg (-2.91, -0.10); P = 0.036], and IL-8 at 8-weeks [-0.18 ng/ml (-0.34, -0.02); P = 0.029] compared to usual care. The MED-diet demonstrated zero adverse events, 91% study completion, 100% attendance, and 81% adherence to the MEDAS. CONCLUSION: The MED-diet is safe and feasible, and has the potential to improve CRF and quality of life in overweight men treated with ADT compared to usual care. Further exploration of the MED-diet is warranted in a larger powered sample size to consolidate these findings. Crown
RCT Entities:
BACKGROUND & AIMS:Cancer-related fatigue (CRF) is a prevalent and persistent symptom from androgen deprivation therapy (ADT) in prostate cancer. The Mediterranean-style dietary pattern (MED-diet) offers a plausible mechanism to mitigate CRF through reducing inflammation and improving body composition. This study aimed to evaluate the effects of a 12-week MED-diet, compared to usual care, on CRF and quality of life in men with prostate cancer treated with ADT. METHODS: Twenty-three men (65.9 ± 7.8 years; body mass index: 29.6 ± 2.7 kg/m2; ADT duration: 33.8 ± 35.6 months) receiving ADT for ≥3 months were randomly assigned (1:1) to 12-weeks of usual care or the MED-diet involving six individualised nutrition consults. Primary outcomes included CRF [Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue scale (FACIT-F) and quality of life [FACIT-General (FACIT-G)], secondary outcomes included body mass/composition and interleukin (IL)-6 and IL-8 concentrations measured at baseline, 8-weeks and 12 weeks. Intervention feasibility was measured by intervention safety, study completion rate, consult attendance, and adherence to the MED-diet through the Mediterranean-diet adherence screener (MEDAS). Intention to treat linear mixed models were used to determine changes in outcomes between the MED-diet and usual care at baseline, 8-weeks and 12-weeks. RESULTS: The MED-diet improved CRF (FACIT-F) at 8-weeks [+4.8 (0.0, 9.8); P = 0.05] and 12-weeks [+7.2 (2.2, 12.0); P = 0.005], quality of life (FACIT-G) at 12-weeks [+9.2 (2.7, 15.8); P = 0.006], reduced total body mass at 8-weeks [-2.51 kg (-4.25, -0.78); P = 0.005] and 12-weeks [-2.97 kg (-4.71, -1.25); P = 0.001], lean mass at 8-weeks [-1.50 kg (-2.91, -0.10); P = 0.036], and IL-8 at 8-weeks [-0.18 ng/ml (-0.34, -0.02); P = 0.029] compared to usual care. The MED-diet demonstrated zero adverse events, 91% study completion, 100% attendance, and 81% adherence to the MEDAS. CONCLUSION: The MED-diet is safe and feasible, and has the potential to improve CRF and quality of life in overweight men treated with ADT compared to usual care. Further exploration of the MED-diet is warranted in a larger powered sample size to consolidate these findings. Crown
Authors: Brenton J Baguley; Kirsten Adlard; David Jenkins; Olivia R L Wright; Tina L Skinner Journal: Int J Environ Res Public Health Date: 2022-05-07 Impact factor: 4.614
Authors: Alix G Sleight; Sylvia L Crowder; Jacek Skarbinski; Paul Coen; Nathan H Parker; Aasha I Hoogland; Brian D Gonzalez; Mary C Playdon; Steven Cole; Jennifer Ose; Yuichi Murayama; Erin M Siegel; Jane C Figueiredo; Heather S L Jim Journal: Cancers (Basel) Date: 2022-04-14 Impact factor: 6.575
Authors: Annie R Curtis; Katherine M Livingstone; Robin M Daly; Laura E Marchese; Nicole Kiss Journal: Int J Environ Res Public Health Date: 2022-02-04 Impact factor: 3.390
Authors: Amber S Kleckner; Brian J Altman; Jennifer E Reschke; Ian R Kleckner; Eva Culakova; Richard F Dunne; Karen M Mustian; Luke J Peppone Journal: J Integr Oncol Date: 2022-05-30
Authors: Rebekah L Wilson; Dennis R Taaffe; Robert U Newton; Nicolas H Hart; Philippa Lyons-Wall; Daniel A Galvão Journal: Nutrients Date: 2021-05-14 Impact factor: 5.717
Authors: Ali Boolani; Karyn M Gallivan; Kristin S Ondrak; Courtney J Christopher; Hector F Castro; Shawn R Campagna; Christopher M Taylor; Meng Luo; Scot E Dowd; Matthew Lee Smith; Lauri O Byerley Journal: Nutrients Date: 2022-01-21 Impact factor: 5.717
Authors: Lisa Umlauff; Manuel Weber; Nils Freitag; Ciaran M Fairman; Axel Heidenreich; Wilhelm Bloch; Moritz Schumann Journal: Prostate Cancer Prostatic Dis Date: 2021-06-30 Impact factor: 5.455